Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the syrian hamster model of lethal Ebola virus infection

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 3, 2011, Pages

  Tsuda, Yoshimi ^a   Safronetz, David ^a   Brown, Kyle ^b,c   Lacasse, Rachel ^a   Marzi, Andrea ^a   Ebihara, Hideki ^a   Feldmann, Heinz ^a,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; RECOMBINANT VACCINE; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ANDES VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFECTION PREVENTION; MALE; NONHUMAN; PRIORITY JOURNAL; SYRIAN HAMSTER; VACCINATION; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; ZAIRE EBOLAVIRUS;

ANIMALS; CERCOPITHECUS AETHIOPS; CRICETINAE; DISEASE MODELS, ANIMAL; EBOLA VACCINES; HEK293 CELLS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MESOCRICETUS; POST-EXPOSURE PROPHYLAXIS; VACCINES, SYNTHETIC; VERO CELLS; VESICULOVIRUS; VIRUS REPLICATION;

EID: 80054749742     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir379     Document Type: Article

References (36)

1. Feldmann H, Geisbert TW, Jahrling PB, et al. Virus taxonomy: Eighth report of the International Committee on Taxonomy of Viruses. In: Fauquet C, Mayo MA, Maniloff J, Desselberger U, Ball LA eds: Filoviridae. London: Elsevier/Academic Press, 2004; 645-53.
2. Pourrut X, Kumulungui B, Wittmann T, et al. The natural history of Ebola virus in Africa. Microbes Infect 2005; 7:1005-14. (Pubitemid 40982668)
3. Sanchez A, Geisbert T, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: knipe D, Howley P, eds: Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2006; 1409-48.
4. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377:849-62.
5. Geisbert TW, Bausch DG, Feldmann H. Prospects for immunization against Marburg and Ebola viruses. Rev Med Virol 2010; 20:344-57.
6. Richardson JS, Dekker JD, Croyle MA, Kobinger GP. Recent advances in Ebolavirus vaccine development. Hum Vaccin 2010; 6:439-49.
7. Falzarano D, Geisbert TW, Feldmann H. Progress in filovirus vaccine development-evaluating the potential for clinical use. Expert Rev Vaccines 2011; 10:63-77.
8. Geisbert TW, Jones S, Fritz EA, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005; 2:e183.
9. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90. (Pubitemid 41021212)
10. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Crossprotection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006; 80:9659-66. (Pubitemid 44435640)
11. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective postexposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.
12. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008; 4:e1000225.
13. Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 2009; 83:7296-304.
14. Geisbert TW, Feldmann H. Vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011. doi: 10.1093/infdis/jir349.
15. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 2001; 75:11677-85. (Pubitemid 33063259)
16. Wang D, Raja NU, Trubey CM, et al. Development of a cAdVax-based bivalent Ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J Virol 2006; 80:2738-46. (Pubitemid 43346369)
17. Pratt WD, Wang D, Nichols DK, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010; 17:572-81.
18. Enria DA, Briggiler AM, Pini N, Levis S. Clinical manifestations of New World hantaviruses. Curr Top Microbiol Immunol 2001; 256:117-34.
19. Khan AS, Young JC. Hantavirus pulmonary syndrome: at the crossroads. Curr Opin Infect Dis 2001; 14:205-9. (Pubitemid 32231108)
20. Ebihara H, Kawaoka Y, Feldmann H. Pathogenesis of filoviruses in small animal models [abstract 2S-7]. In: Program and abstracts of the 5th International Symposium of Filoviruses. Tokyo, 2010;29 pp.
21. Hooper JW, Larsen T, Custer DM, Schmaljohn CS. A lethal disease model for hantavirus pulmonary syndrome. Virology 2001; 289:6-14. (Pubitemid 33016232)
22. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61. (Pubitemid 28397211)
23. Ebihara H, Takada A, Kobasa D, et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2006; 2:e73.
24. Safronetz D, Hegde NR, Ebihara H, et al. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J Virol 2009; 83:7285-95.
25. Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179(Suppl 1):S177-87. (Pubitemid 29091400)
26. Ebihara H, Yoshimatsu K, Ogino M, et al. Pathogenicity of Hantaan virus in newborn mice: genetic reassortant study demonstrating that a single amino acid change in glycoprotein G1 is related to virulence. J Virol 2000; 74:9245-55.
27. Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A 1996; 93:11359-65. (Pubitemid 26347126)
28. Takada A, Feldmann H, Stroeher U, et al. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol 2003; 77:1069-74. (Pubitemid 36055528)
29. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replicationcompetent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65. (Pubitemid 38581495)
30. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4. (Pubitemid 36987993)
31. Wahl-Jensen V, Kurz SK, Hazelton PR, et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 2005; 79:2413-9. (Pubitemid 40204596)
32. Nakayama E, Yokoyama A, Miyamoto H, et al. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol 2010; 17:1723-8.
33. Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 2004; 6:1-24.
34. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers.Lancet Infect Dis 2004; 4:487-98. (Pubitemid 39077918)
35. Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003; 163:2371-82. (Pubitemid 37474154)
36. Simpson SQ, Spikes L, Patel S, Faruqi I. Hantavirus pulmonary syndrome. Infect Dis Clin North Am 2010; 24:159-73.